Aqilion strengthens its operational team in preclinical development
Aqilion announced today that Anneli Hällgren has been appointed the new head of preclinical development, including regulatory safety studies. Anneli has worked for the past ten years as a consultant in preclinical drug discovery and will now join the Aqilion team on a part-time basis. Anneli Hällgren holds a PhD in physiology from Uppsala University, Sweden, and has more than 20 years of experience in research and development projects with a focus on a variety of indications and disease areas, including inflammatory and autoimmune conditions. Her career began at AstraZeneca, where she